Exforge HCT

Country: Evrópusambandið

Tungumál: enska

Heimild: EMA (European Medicines Agency)

Kauptu það núna

Vara einkenni Vara einkenni (SPC)
29-09-2023
Opinber matsskýrsla Opinber matsskýrsla (PAR)
20-12-2013

Virkt innihaldsefni:

valsartan, hydrochlorothiazide, Amlodipine besilate

Fáanlegur frá:

Novartis Europharm Limited

ATC númer:

C09DX01

INN (Alþjóðlegt nafn):

amlodipine besilate, valsartan, hydrochlorothiazide

Meðferðarhópur:

Agents acting on the renin-angiotensin system

Lækningarsvæði:

Hypertension

Ábendingar:

Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.

Vörulýsing:

Revision: 24

Leyfisstaða:

Authorised

Leyfisdagur:

2009-10-15

Upplýsingar fylgiseðill

                                74
B. PACKAGE LEAFLET
75
PACKAGE LEAFLET: INFORMATION FOR THE USER
EXFORGE HCT 5 MG/160 MG/12.5 MG FILM-COATED TABLETS
EXFORGE HCT 10 MG/160 MG/12.5 MG FILM-COATED TABLETS
EXFORGE HCT 5 MG/160 MG/25 MG FILM-COATED TABLETS
EXFORGE HCT 10 MG/160 MG/25 MG FILM-COATED TABLETS
EXFORGE HCT 10 MG/320 MG/25 MG FILM-COATED TABLETS
amlodipine/valsartan/hydrochlorothiazide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Exforge HCT is and what it is used for
2.
What you need to know before you take Exforge HCT
3.
How to take Exforge HCT
4.
Possible side effects
5.
How to store Exforge HCT
6.
Contents of the pack and other information
1.
WHAT EXFORGE HCT IS AND WHAT IT IS USED FOR
Exforge HCT tablets contain three substances called amlodipine,
valsartan and hydrochlorothiazide.
All of these substances help to control high blood pressure.
−
Amlodipine belongs to a group of substances called “calcium channel
blockers”. Amlodipine
stops calcium from moving into the blood vessel wall, which stops the
blood vessels from
tightening.
−
Valsartan belongs to a group of substances called “angiotensin-II
receptor antagonists”.
Angiotensin II is produced by the body and makes the blood vessels
tighten, thus increasing the
blood pressure. Valsartan works by blocking the effect of angiotensin
II.
−
Hydrochlorothiazide belongs to a group of substances called
“thiazide diuretics”.
Hydrochlorothiazide increases urine output, which also lowers blood
pressure.
As a result of all three mechanisms, the blood v
                                
                                Lestu allt skjalið
                                
                            

Vara einkenni

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Exforge HCT 5 mg/160 mg/12.5 mg film-coated tablets
Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets
Exforge HCT 5 mg/160 mg/25 mg film-coated tablets
Exforge HCT 10 mg/160 mg/25 mg film-coated tablets
Exforge HCT 10 mg/320 mg/25 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Exforge HCT 5 mg/160 mg/12.5 mg film-coated tablets
Each film-coated tablet contains 5 mg of amlodipine (as amlodipine
besylate), 160 mg of valsartan,
and 12.5 mg of hydrochlorothiazide.
Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets
Each film-coated tablet contains 10 mg of amlodipine (as amlodipine
besylate), 160 mg of valsartan,
and 12.5 mg of hydrochlorothiazide.
Exforge HCT 5 mg/160 mg/25 mg film-coated tablets
Each film-coated tablet contains 5 mg of amlodipine (as amlodipine
besylate), 160 mg of valsartan,
and 25 mg of hydrochlorothiazide.
Exforge HCT 10 mg/160 mg/25 mg film-coated tablets
Each film-coated tablet contains 10 mg of amlodipine (as amlodipine
besylate), 160 mg of valsartan,
and 25 mg of hydrochlorothiazide.
Exforge HCT 10 mg/320 mg/25 mg film-coated tablets
Each film-coated tablet contains 10 mg of amlodipine (as amlodipine
besylate), 320 mg of valsartan
and 25 mg of hydrochlorothiazide.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet)
Exforge HCT 5 mg/160 mg/12.5 mg film-coated tablets
White, ovaloid, biconvex tablets with bevelled edge, debossed
“NVR” on one side and “VCL” on the
other side. Approximate size: 15 mm (length) x 5.9 mm (width).
Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets
Pale yellow, ovaloid, biconvex tablets with bevelled edge, debossed
“NVR” on one side and “VDL”
on the other side. Approximate size: 15 mm (length) x 5.9 mm (width).
Exforge HCT 5 mg/160 mg/25 mg film-coated tablets
Yellow, ovaloid, biconvex tablets with bevelled edge, debossed
“NVR” on one side and “VEL” on the
other side. Approximate size: 15 mm
                                
                                Lestu allt skjalið
                                
                            

Skjöl á öðrum tungumálum

Upplýsingar fylgiseðill Upplýsingar fylgiseðill búlgarska 29-09-2023
Vara einkenni Vara einkenni búlgarska 29-09-2023
Opinber matsskýrsla Opinber matsskýrsla búlgarska 12-12-2013
Upplýsingar fylgiseðill Upplýsingar fylgiseðill spænska 29-09-2023
Vara einkenni Vara einkenni spænska 29-09-2023
Opinber matsskýrsla Opinber matsskýrsla spænska 12-12-2013
Upplýsingar fylgiseðill Upplýsingar fylgiseðill tékkneska 29-09-2023
Vara einkenni Vara einkenni tékkneska 29-09-2023
Opinber matsskýrsla Opinber matsskýrsla tékkneska 12-12-2013
Upplýsingar fylgiseðill Upplýsingar fylgiseðill danska 29-09-2023
Vara einkenni Vara einkenni danska 29-09-2023
Opinber matsskýrsla Opinber matsskýrsla danska 12-12-2013
Upplýsingar fylgiseðill Upplýsingar fylgiseðill þýska 29-09-2023
Vara einkenni Vara einkenni þýska 29-09-2023
Opinber matsskýrsla Opinber matsskýrsla þýska 12-12-2013
Upplýsingar fylgiseðill Upplýsingar fylgiseðill eistneska 29-09-2023
Vara einkenni Vara einkenni eistneska 29-09-2023
Opinber matsskýrsla Opinber matsskýrsla eistneska 12-12-2013
Upplýsingar fylgiseðill Upplýsingar fylgiseðill gríska 29-09-2023
Vara einkenni Vara einkenni gríska 29-09-2023
Opinber matsskýrsla Opinber matsskýrsla gríska 12-12-2013
Upplýsingar fylgiseðill Upplýsingar fylgiseðill franska 29-09-2023
Vara einkenni Vara einkenni franska 29-09-2023
Opinber matsskýrsla Opinber matsskýrsla franska 12-12-2013
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ítalska 29-09-2023
Vara einkenni Vara einkenni ítalska 29-09-2023
Opinber matsskýrsla Opinber matsskýrsla ítalska 12-12-2013
Upplýsingar fylgiseðill Upplýsingar fylgiseðill lettneska 29-09-2023
Vara einkenni Vara einkenni lettneska 29-09-2023
Opinber matsskýrsla Opinber matsskýrsla lettneska 12-12-2013
Upplýsingar fylgiseðill Upplýsingar fylgiseðill litháíska 29-09-2023
Vara einkenni Vara einkenni litháíska 29-09-2023
Opinber matsskýrsla Opinber matsskýrsla litháíska 12-12-2013
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ungverska 29-09-2023
Vara einkenni Vara einkenni ungverska 29-09-2023
Opinber matsskýrsla Opinber matsskýrsla ungverska 12-12-2013
Upplýsingar fylgiseðill Upplýsingar fylgiseðill maltneska 29-09-2023
Vara einkenni Vara einkenni maltneska 29-09-2023
Opinber matsskýrsla Opinber matsskýrsla maltneska 12-12-2013
Upplýsingar fylgiseðill Upplýsingar fylgiseðill hollenska 29-09-2023
Vara einkenni Vara einkenni hollenska 29-09-2023
Opinber matsskýrsla Opinber matsskýrsla hollenska 12-12-2013
Upplýsingar fylgiseðill Upplýsingar fylgiseðill pólska 29-09-2023
Vara einkenni Vara einkenni pólska 29-09-2023
Opinber matsskýrsla Opinber matsskýrsla pólska 12-12-2013
Upplýsingar fylgiseðill Upplýsingar fylgiseðill portúgalska 29-09-2023
Vara einkenni Vara einkenni portúgalska 29-09-2023
Opinber matsskýrsla Opinber matsskýrsla portúgalska 12-12-2013
Upplýsingar fylgiseðill Upplýsingar fylgiseðill rúmenska 29-09-2023
Vara einkenni Vara einkenni rúmenska 29-09-2023
Opinber matsskýrsla Opinber matsskýrsla rúmenska 12-12-2013
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvakíska 29-09-2023
Vara einkenni Vara einkenni slóvakíska 29-09-2023
Opinber matsskýrsla Opinber matsskýrsla slóvakíska 12-12-2013
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvenska 29-09-2023
Vara einkenni Vara einkenni slóvenska 29-09-2023
Opinber matsskýrsla Opinber matsskýrsla slóvenska 12-12-2013
Upplýsingar fylgiseðill Upplýsingar fylgiseðill finnska 29-09-2023
Vara einkenni Vara einkenni finnska 29-09-2023
Opinber matsskýrsla Opinber matsskýrsla finnska 12-12-2013
Upplýsingar fylgiseðill Upplýsingar fylgiseðill sænska 29-09-2023
Vara einkenni Vara einkenni sænska 29-09-2023
Opinber matsskýrsla Opinber matsskýrsla sænska 12-12-2013
Upplýsingar fylgiseðill Upplýsingar fylgiseðill norska 29-09-2023
Vara einkenni Vara einkenni norska 29-09-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill íslenska 29-09-2023
Vara einkenni Vara einkenni íslenska 29-09-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill króatíska 29-09-2023
Vara einkenni Vara einkenni króatíska 29-09-2023
Opinber matsskýrsla Opinber matsskýrsla króatíska 12-12-2013

Skoða skjalasögu